Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enovis Corporation filings document the formal disclosures of a public medical technology company with Reconstructive and Prevention & Recovery operations. Recent Form 8-K reports cover quarterly and annual results, furnished earnings releases, conference presentation materials and Regulation FD disclosures tied to management presentations.
The filing record also includes proxy materials for annual meeting governance, board and executive compensation matters, executive transition disclosures, and material financing agreements. Enovis filings describe credit facilities, leverage covenants, guarantor arrangements, senior unsecured convertible notes references, financial condition, segment performance and related risk and governance subjects.
Shirley Brady reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Shirley Brady received a grant of 9,346 shares of common stock on May 19, 2026. The shares were awarded at no stated price as compensation rather than a market purchase. After this award, Brady directly holds a total of 110,589 Enovis common shares.
Bodem Barbara W. reported acquisition or exercise transactions in this Form 4 filing.
Enovis Corp director Barbara W. Bodem received an equity award of 9,346 shares of common stock on May 19, 2026. The shares were granted at no cash cost to her, reflecting stock-based compensation rather than an open-market purchase. After this award, she directly owns 24,201 Enovis common shares.
Enovis CORP director Philip Okala received a grant of 9,346 shares of common stock. The award was recorded on May 19, 2026 at a stated price of $0.00 per share, indicating it was a compensation-related equity grant rather than an open-market purchase.
After this grant, Okala directly holds a total of 24,201 shares of Enovis common stock. The filing does not show any share sales, option exercises, or derivative positions; it only reports this single stock award and the resulting direct ownership level.
Ortiz Christine reported acquisition or exercise transactions in this Form 4 filing.
Enovis Corp director Christine Ortiz received a grant of company stock. On May 19, 2026, she was awarded 9,346 shares of Enovis common stock at no purchase price as a compensation-related grant. After this award, she directly owns 25,011 common shares of Enovis.
This was a stock grant, not an open-market purchase or sale, and reflects routine equity-based compensation rather than a discretionary trade in the market.
Lalor Angela S reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Angela S. Lalor received a stock grant of 9,346 shares of common stock on May 19, 2026. The award was recorded at a price of $0.00 per share, indicating a compensation-related grant rather than an open-market purchase. Following this grant, she directly holds 31,486 Enovis common shares.
PERFALL A CLAYTON reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director A. Clayton Perfall reported a stock grant and updated holdings. The filing shows a grant or award of 9,346 shares of common stock at no cash cost, bringing his directly held stake to 54,190 shares. A separate entry reports indirect ownership of 2,482 shares held by a trust.
The transactions are compensation and ownership updates rather than open-market buying or selling, so they mainly clarify the director’s equity position in Enovis.
Kelly Liam reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Liam Kelly received a grant of 9,346 shares of common stock. The award was reported at a price of $0.00 per share, indicating it was a compensation-related grant rather than an open-market purchase. Following this grant, Kelly directly holds a total of 28,950 Enovis common shares.
Wienbar Sharon L reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Sharon L. Wienbar received a grant of 9,346 shares of common stock on May 19, 2026. The shares were awarded at a stated price of $0.00 per share, indicating a compensation-related grant rather than an open-market purchase. Following this award, she directly holds 41,946 shares of Enovis common stock.
Vinnakota Rajiv reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Rajiv Vinnakota received a grant of 9,346 shares of common stock on May 19, 2026 at no cost as an equity award. This increased his directly held stake to 37,608 shares. The transaction reflects routine stock-based compensation, not an open-market purchase or sale.
Enovis Corporation reported the results of its Annual Meeting held on May 19, 2026. Stockholders approved an amendment to the 2020 Omnibus Incentive Plan that authorizes an additional 3,650,000 shares of common stock for equity awards and raises the annual compensation cap for each Outside Director from $350,000 to $750,000, with up to 200% of that limit allowed in certain first-year or leadership appointment situations.
All ten director nominees were elected, each receiving over 50 million votes in favor with relatively few votes against. Stockholders ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers. The plan amendment will be implemented through a Form S-8 registration of the additional shares.